Transforming cannabis into scientifically proven and clinically approved medical solutions
OWC Pharmaceutical Research Corp. aspires to realize the potential of medical cannabis research and develops medicinal products, specifically designed to improve the lives of millions.
We fuse the freshness and the visionary approach of an innovative company with the wisdom and the knowledge of experienced players in the pharmaceutical industry and in cannabis-based treatment, by incorporating cutting-edge research, proven global experience and unprecedented professionalism of our people.
TOPICAL OINTMENT FOR SKIN DISEASES
Whilst potentially suitable for multiple skin conditions, the initial indication for OWC’s topical ointment is for Psoriasis. The ointment contains high and unprecedented concentrations of CBD and THC that proved safe and tolerable with no psycho-active side effects in a clinical trial. In pre-clinical studies, our cannabinoid-based topical ointment demonstrated up to a 70 percent reduction in Psoriasis-related biomarkers.
SUBLINGUAL DISINTEGRATING TABLET
Research and Development
Headquartered in Israel, OWC R&D is focused on discovering and developing cannabis-based novel products and therapies, designed for treating specific medical conditions and alleviating certain disease-associated symptoms.
OWC leverages its extensive network, comprising some of Israel’s leading researchers, scientists, academic and medical centers, as well as cannabis breeders and extractors, to unlock the potential of cannabis for diverse therapeutic applications. OWC research is dedicated to provide patients with the assurance that they are using products that are chemically characterized, clinically tested, safe to use and efficient. Product development and manufacturing are conducted according to the Israeli Ministry of Health and quality regulations (such as: GAP, GLP GMP and GCP).
New at OWC
OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy.
Our newly developed, highly concentrated formulation, OWC-1808, was administered in vivo for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability, and will be directed initially at our ongoing program for treating Multiple Myeloma.
OWC Pharmaceutical Research Corp. to report progress in clinical trials for ointment care for skin diseases.
The first ever safety study of cannabis-based topical ointment, conducted at Sheba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The study is expected to be completed by the end of December 2018.
OWC Pharmaceutical Research Corp Completes Development of Next Generation Orally-Disintegrating Tablet.
OWC Pharmaceutical has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). The tablet is targeted at different indications and will be available in various ratios of THC to CBD and various doses of these actives.